<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10039">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057705</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-101-13</org_study_id>
    <nct_id>NCT02057705</nct_id>
  </id_info>
  <brief_title>Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)</brief_title>
  <acronym>MTM</acronym>
  <official_title>Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valerion Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valerion Therapeutics, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-interventional, longitudinal study of the natural history and
      function of approximately 60 patients with MTM from the United States, Canada and Europe.
      The duration of the study, including the enrollment period, will be 36 months.  Data from
      the study will be used to characterize the disease course of MTM and determine which outcome
      measures will be the best to assess the efficacy of potential therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Time to characterize the disease course in MTM patients</measure>
    <time_frame>Up to 24 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study-specific functional assessments and patient questionnaires will be used and will be based on the age and ambulatory status of the participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease severity and disease progression</measure>
    <time_frame>Baseline, Month 3 (EU only), Month 6, Month 12 and Month 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study-specific functional assessments and patient questionnaires will be used and will be based on the age and ambulatory status of the participant</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with an immune response against adeno-associated virus (AAV)</measure>
    <time_frame>Baseline Visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 5 ml sample of whole blood will be collected during the study to assess the immunity against various AAV serotypes.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myotubular Myopathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  5 ml sample of whole blood will be collected during the study to assess the immunity
           against various AAV serotypes

        -  5 ml blood sample may be obtained for peripheral blood mononuclear cells (PBMC) to
           quantify X-linked myotubular myopathy gene 1 (MTM1) production

        -  24-hour urine collection will be performed every 6 months in order to measure urinary
           creatinine excretion

        -  Slides and tissue from a previously performed muscle biopsy will be obtained for a
           central review and quantification of histo- and immunohistopathological features of MTM
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Investigative Research Centers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients of any age (newborns included) may participate.

          -  Patients over 18 years of age and parent(s)/legal guardian(s) of patients &lt;18 years
             of age must provide written informed consent prior to participating in the study and
             informed assent will be obtained from minors at least 7 years of age when required by
             regulation.

          -  MTM resulting from a mutation in the MTM1 gene.

          -  Male or symptomatic female. A symptomatic female will be defined by the motor
             function assessment by Motor Function Measure (MFM) or North Star Ambulatory
             Assessment (NSAA) below 80% of the total score.

          -  Willing and able to comply with all protocol requirements and procedures.

        Exclusion criteria:

          -  Other disease which may significantly interfere with the assessment of MTM and is
             clearly not related to the disease.

          -  Currently enrolled in a treatment study; or treatment with an experimental therapy
             other than pyridostigmine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hal Landy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Valerion Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Nelken</last_name>
    <phone>617-755-4149</phone>
    <email>michelle.nelken@alopexx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Health, Neuroscience Research Center Building 35, Room 2A-116 MSC 3705 35 Convent Drive</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-3705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike Averion</last_name>
      <phone>301-594-2760</phone>
      <email>averion.gilberto@nih.gov</email>
    </contact>
    <investigator>
      <last_name>Carsten Bonnemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital, 300 Longwood Avenue</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Szelag</last_name>
      <phone>617-355-6388</phone>
      <email>heather.szelag@children's.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Basil Darras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children, 555 University Avenue</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Amburgey</last_name>
      <phone>(416) 813-7654</phone>
      <phone_ext>301707</phone_ext>
      <email>kim.amburgey@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>James Dowling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie, GH Pitié Salpêtrière, Bâtiment Babinski</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Annoussamy</last_name>
      <phone>+33 1 42 16 66 49</phone>
      <email>m.annoussamy@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Laurent Servais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/x-linked-myotubular-myopathy</url>
    <description>National Institute of Health</description>
  </link>
  <link>
    <url>http://www.muscular-dystrophy.org/about_muscular_dystrophy/conditions/114_myotubular_centronuclear_myopathy</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <link>
    <url>http://www.orpha.net</url>
    <description>Orphanet</description>
  </link>
  <reference>
    <citation>Herman GE, Finegold M, Zhao W, de Gouyon B, Metzenberg A. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr. 1999 Feb;134(2):206-14.</citation>
    <PMID>9931531</PMID>
  </reference>
  <reference>
    <citation>Jungbluth H, Sewry CA, Buj-Bello A, Kristiansen M, Ørstavik KH, Kelsey A, Manzur AY, Mercuri E, Wallgren-Pettersson C, Muntoni F. Early and severe presentation of X-linked myotubular myopathy in a girl with skewed X-inactivation. Neuromuscul Disord. 2003 Jan;13(1):55-9.</citation>
    <PMID>12467733</PMID>
  </reference>
  <reference>
    <citation>McEntagart M, Parsons G, Buj-Bello A, Biancalana V, Fenton I, Little M, Krawczak M, Thomas N, Herman G, Clarke A, Wallgren-Pettersson C. Genotype-phenotype correlations in X-linked myotubular myopathy. Neuromuscul Disord. 2002 Dec;12(10):939-46.</citation>
    <PMID>12467749</PMID>
  </reference>
  <reference>
    <citation>Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis. 2008 Sep 25;3:26. doi: 10.1186/1750-1172-3-26. Review.</citation>
    <PMID>18817572</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MTM</keyword>
  <keyword>myotubular myopathy</keyword>
  <keyword>X-linked centronuclear myopathy</keyword>
  <keyword>inherited myopathies</keyword>
  <keyword>neuromuscular diseases</keyword>
  <keyword>hypotonia</keyword>
  <keyword>genetic mutation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
